SAN JOSE, Calif., July 10, 2020 /PRNewswire/ -- Anixa Biosciences,
Inc. (NASDAQ: ANIX), a biotechnology company focused on the
treatment and prevention of cancer and infectious diseases, today
announced that the European Patent Office has issued an Intention
to Grant notice for the first European patent covering Anixa's
novel CAR-T cancer treatment technology, which has been licensed
from The Wistar Institute and is being developed at the Moffitt
Cancer Center.
The patent is titled "METHODS AND COMPOSITIONS FOR TREATING
CANCER," and the inventors are Drs. Jose
Conejo-Garcia and Alfredo
Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the
Department of Immunology at Moffitt Cancer Center and Dr.
Alfredo Perales-Puchalt, formerly of
The Wistar Institute, is currently Vice President of R&D at
Geneos Therapeutics. The patent is assigned to The Wistar
Institute and Anixa Biosciences' majority-owned subsidiary,
Certainty Therapeutics, Inc., is the exclusive, world-wide
licensee.
Dr. Amit Kumar, President and CEO
of Anixa Biosciences, stated, "We are pleased to receive this
notification from the European Patent Office (EPO), and the
protection this groundbreaking technology will have throughout the
European Union, in addition to the existing patents in the United States. Our CAR-T cancer
technology takes advantage of specific hormone–hormone receptor
biology to address malignancies and may hold promise to be the
first successful CAR-T therapy against solid tumors. While
our initial focus is the treatment of ovarian cancer, the
technology covered by the patent is broad and may also be effective
in treating other solid tumors by exploiting an anti-angiogenesis
mechanism of action."
"Protecting intellectual property is critical for the
advancement of new therapies, such as our CAR-T technology, which
has been exclusively licensed to Anixa's subsidiary, Certainty
Therapeutics. As a minority shareholder of Certainty, we are
looking forward to continued advancement of the therapy into the
clinic where we hope this will help many cancer patients," said
Heather Steinman, PhD, MBA, Vice
President of Business Development at The Wistar
Institute.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutic portfolio includes a cancer immunotherapy program which
uses a novel type of CAR-T, known as chimeric endocrine receptor
T-cell (CER-T) technology, and a Covid-19 therapeutics program
focused on inhibiting certain viral protein function. The
company's vaccine portfolio consists of a technology focused on the
immunization against α-Lactalbumin to prevent triple negative
breast cancer (TNBC). Anixa continually examines emerging
technologies in complementary fields for further development and
commercialization. Additional information is available at
www.anixa.com.
About The Wistar Institute
The Wistar Institute is an
international leader in biomedical research with special expertise
in cancer research and vaccine development. Founded in 1892
as the first independent nonprofit biomedical research institute in
the United States, Wistar has held
the prestigious Cancer Center designation from the National Cancer
Institute since 1972. The Institute works actively to ensure
that research advances move from the laboratory to the clinic as
quickly as possible. wistar.org
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-car-t-cancer-therapy-receives-intention-to-grant-notice-from-the-european-patent-office-301091266.html
SOURCE Anixa Biosciences, Inc.